ARX 788

Drug Profile

ARX 788

Alternative Names: Antibody-drug conjugate - Ambrx/Zhejiang Medicine; ARX788

Latest Information Update: 22 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ambrx
  • Developer Ambrx; Zhejiang Medicine
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies; Small molecules
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • Preclinical Gastric cancer

Most Recent Events

  • 23 Aug 2017 Ambrx plans a phase I trial for Cancer (Late-stage disease, Second-line therapy or greater) (NCT03255070)
  • 19 Aug 2016 The US FDA approves IND application for a phase I trial of ARX 788
  • 25 Mar 2016 IND application for ARX 788 in Breast cancer was approved in Australia and New Zealand before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top